NO974995L - Estere av karbapenemer - Google Patents

Estere av karbapenemer

Info

Publication number
NO974995L
NO974995L NO974995A NO974995A NO974995L NO 974995 L NO974995 L NO 974995L NO 974995 A NO974995 A NO 974995A NO 974995 A NO974995 A NO 974995A NO 974995 L NO974995 L NO 974995L
Authority
NO
Norway
Prior art keywords
hydrogen
group
alkyl
optionally substituted
formula
Prior art date
Application number
NO974995A
Other languages
English (en)
Norwegian (no)
Other versions
NO974995D0 (no
Inventor
George Burton
Stephen Christopher Marti Fell
Stephen Frederick Moss
Alfred John Eglington
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9508960.3A external-priority patent/GB9508960D0/en
Priority claimed from GBGB9508959.5A external-priority patent/GB9508959D0/en
Priority claimed from GBGB9508964.5A external-priority patent/GB9508964D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO974995D0 publication Critical patent/NO974995D0/no
Publication of NO974995L publication Critical patent/NO974995L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/14—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation
    • C07D477/06—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • C07D477/08—Modification of a carboxyl group directly attached in position 2, e.g. esterification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO974995A 1995-05-03 1997-10-30 Estere av karbapenemer NO974995L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9508960.3A GB9508960D0 (en) 1995-05-03 1995-05-03 Novel compounds
GBGB9508959.5A GB9508959D0 (en) 1995-05-03 1995-05-03 Novel compounds
GBGB9508964.5A GB9508964D0 (en) 1995-05-03 1995-05-03 Novel compounds
PCT/EP1996/001882 WO1996034869A1 (en) 1995-05-03 1996-05-02 Esters of carbapenems

Publications (2)

Publication Number Publication Date
NO974995D0 NO974995D0 (no) 1997-10-30
NO974995L true NO974995L (no) 1997-10-30

Family

ID=27267697

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974995A NO974995L (no) 1995-05-03 1997-10-30 Estere av karbapenemer

Country Status (14)

Country Link
EP (1) EP0823911A1 (tr)
JP (1) JPH11504912A (tr)
KR (1) KR19990008354A (tr)
CN (1) CN1184480A (tr)
AU (1) AU5814196A (tr)
BR (1) BR9608318A (tr)
CA (1) CA2217885A1 (tr)
CZ (1) CZ347697A3 (tr)
HU (1) HUP9801061A3 (tr)
MX (1) MX9708422A (tr)
NO (1) NO974995L (tr)
PL (1) PL323148A1 (tr)
TR (1) TR199701289T2 (tr)
WO (1) WO1996034869A1 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100771019B1 (ko) * 2002-03-20 2007-10-29 주식회사 만도 브레이크 액압제어장치
GB0400329D0 (en) * 2004-01-08 2004-02-11 Glaxo Group Ltd Novel processes
GB0400405D0 (en) * 2004-01-09 2004-02-11 Glaxo Group Ltd Novel processes
JP2007039383A (ja) * 2005-08-03 2007-02-15 Dainippon Sumitomo Pharma Co Ltd アリールカルバペネム化合物の製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593524A (en) * 1976-11-19 1981-07-15 Merck & Co Inc 1-carba-2-penem-3-carboxylic acids
DK637888A (da) * 1987-11-24 1989-05-25 Hoffmann La Roche Carboxylsyreestere
GB8809534D0 (en) * 1988-04-22 1988-05-25 Beecham Group Plc Novel compounds
SK53696A3 (en) * 1993-10-29 1996-10-02 Smithkline Beecham Plc Carbapenem derivatives, their preparation, pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
CZ347697A3 (cs) 1998-06-17
CN1184480A (zh) 1998-06-10
MX9708422A (es) 1998-02-28
TR199701289T2 (tr) 1998-08-21
BR9608318A (pt) 1999-01-26
AU5814196A (en) 1996-11-21
JPH11504912A (ja) 1999-05-11
NO974995D0 (no) 1997-10-30
KR19990008354A (ko) 1999-01-25
HUP9801061A2 (hu) 1998-08-28
HUP9801061A3 (en) 1999-01-28
PL323148A1 (en) 1998-03-16
EP0823911A1 (en) 1998-02-18
CA2217885A1 (en) 1996-11-07
WO1996034869A1 (en) 1996-11-07

Similar Documents

Publication Publication Date Title
DK0870765T3 (da) Aminothiazolderivat, lægemiddel indeholdende samme og mellemprodukt til fremstilling af forbindelsen
TR200400541T4 (tr) Terapide faydalı tropan türevleri.
HRP20020175B1 (en) N-heterocyclikc derivatives as nos inhibitors
NO20065012L (no) Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse
NO982913L (no) Kinolin- og kinazolinforbindelser nyttige i terapi
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
NO883487L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
NO20015446L (no) Kinolin-derivater som inhibitorer for MEK-enzymer
HUP0001396A2 (hu) 3-Amino-3 aril-propán-1-ol-származékok, előállításuk és felhasználásuk
EP1468692A3 (en) Use of 2,6-di-alkyl-4-silyl-phenols for treating xanthoma
NO974995L (no) Estere av karbapenemer
DK0785789T3 (da) Diazepinindoler som phosphodiesterase IV-inhibitorer
CA2301967A1 (en) Azetidinone derivatives for the treatment of hcmv infections
MXPA03011032A (es) Activadores de derivados de oxazol/tiazol del receptor hppar-alfa.
DE69201184D1 (de) 5- Piperazinylalkyl-1,5-Benzothiazepinone verwendbar als Calciumantagonisten.
PT1021404E (pt) Derivados de azetidinona para o tratamento de infeccoes pelo hcmv
BG100551A (en) 2-(pyrazol-3-yl)carbapenem derivatives
DE69131774T2 (de) Antibakterielle penem-ester derivate
ES2174077T3 (es) Derivados de hidroxilamina antiisquemicos y composiciones farmaceuticas.
EA200500028A1 (ru) Новые соединения 3-(4-оксо-4h-хромен-2-ил)-(1h)-хинолин-4-она, способ их получения и фармацевтические композиции, которые их содержат
HUP0002715A2 (hu) Benzotiofénszármazékok alkalmazása trombocitaszám csökkentésére szolgáló gyógyszerkészítmények előállítására
NO955071L (no) abeo-Ergolin-derivater som 5HT1A-ligander
DK0532725T3 (da) Isoxazolderivater som lysfilterpræparater
NO974759L (no) Cefalosporinpyridiniumderivater
NO940321L (no) Forbindelser med angiotensin II - antagonistisk aktivitet